Bank Julius Baer & Co. A.G., Guernsey Branch Stock

Certificat

SBGAJB

CH1319611179

Market Closed - Bid/Ask 11:20:00 2024-05-17 EDT After market 11:15:00
102.9 CHF +0.10% Intraday chart for Bank Julius Baer & Co. A.G., Guernsey Branch 102.8 -0.10%
1 month+0.93%
3 months+1.43%

Static data

Product typeReverse Convertibles
Buy / SellCALL
Underlying BASILEA PHARMACEUTICA AG
Issuer Bank Julius Bär
SBGAJB
ISINCH1319611179
Date issued 2024-01-30
Strike 34.05 CHF
Maturity 2025-01-30 (241 Days)
Parity 0.03 : 1
Emission price 100 CHF
Emission volume N/A
Settlement both
Currency CHF

Technical Indicators

Highest since issue 103.3 CHF
Lowest since issue 97.1 CHF
Spread 5 CHF
Spread %0.49%

Company Profile

Basilea Pharmaceutica AG Allschwil, formerly known as Basilea Pharmaceutica AG, is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. It launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.
Sector
-
More about the company

Ratings for Basilea Pharmaceutica AG

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Basilea Pharmaceutica AG

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
43.7 CHF
Average target price
70.58 CHF
Spread / Average Target
+61.52%
Consensus
  1. Stock Market
  2. Certificates
  3. SBGAJB Certificat